Promakhos Therapeutics

Promakhos Therapeutics is developing a novel therapeutics platform leveraging bacterial molecules to stimulate the body's inherent capacity for inflammation control and healing. Their initial focus is on Crohn's Disease, a condition affecting over half a million individuals in the United States and incurring annual costs of $10 billion. Following their work on Crohn's disease, Promakhos plans to expand their platform to address Type 1 Diabetes and Multiple Sclerosis, aiming to provide innovative treatment options for these chronic inflammatory disorders.